89bio announces appointment of kathy laporte to its board of directors

San francisco, nov. 03, 2021 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of kathy laporte to its board of directors, effective immediately. ms. laporte brings deep expertise and valuable experience in the industry to the company.
ETNB Ratings Summary
ETNB Quant Ranking